THERE’S A VACCINE FOR THAT

Pilot Program to Curb Rise in HPV-Positive Throat Cancers

Human papillomavirus (HPV) is the most common sexually transmitted disease and is probably best known as the leading cause of cervical cancer. Thanks to increased awareness, preventive screenings and the introduction of an HPV vaccine in 2006, the incidence of new cervical cancer has declined in the United States. Unfortunately, other HPV-positive cancers are on the rise. Oropharyngeal (throat) cancer is now the leading cancer caused by HPV. A cancer that predominately affects men, there is still little public awareness about it or its prevention.

As a head and neck surgical oncologist specializing in HPV-related cancers, Daniel Faden, MD, sees how destructive oropharyngeal cancers can be. Aside from the life-threatening cancer itself, treatment for HPV-positive oropharyngeal tumors has profound effects on daily life and function, affecting speech and swallowing and negatively impacting quality of life. It is especially tragic since HPV-positive throat cancers in both men and women are preventable with a vaccine. In 2009, the FDA specifically approved the use of Gardasil 9 for the prevention of oropharyngeal cancers for males ages nine through 45. The FDA’s announcement, combined with the rising rate of these cancers, low vaccination rates and a general lack of knowledge regarding the relationship between HPV and throat cancer, prompted Faden and a team of physicians and nurses at BMC’s Department of Otolaryngology-Head and Neck Surgery to set up a pilot point-of-care HPV vaccination clinic to help improve vaccination rates.

So far, Faden is encouraged by the number of patients interested in vaccination. The department is vaccinating about 10 percent of participants who fill out the survey, higher than what they anticipated. The research team is now analyzing the survey responses to understand what barriers exist to vaccination and will then design interventions to help overcome these barriers. Ultimately, the goal is to protect more people from developing cancer by making the vaccine more accessible to those eligible. To a surgeon who spends his days on the front lines of cancer treatment, the old adage “an ounce of prevention is worth a pound of cure,” rings particularly true.

“Vaccinating patients may potentially completely abrogate the development of a cancer later in life, which is amazing to think about, right?” Faden emphasizes. “I spend my career researching the molecular underpinnings of HPV-related head and neck cancers so we can better treat patients who already have cancer, when we could just prevent them from getting it in the first place by giving them a few painless shots.”